High-Dose CBD Shows Promise for Nerve Pain After Spinal Injury

For many people living with a spinal cord injury, the injury itself is only part of the challenge. Long after the initial trauma, chronic neuropathic pain can become a daily reality. This type of pain originates from damage to the nervous system and is often described as burning, stabbing, tingling, or electric shock-like sensations. Unfortunately, available treatments do not always provide adequate relief, and many can come with unwanted side effects.

As interest in cannabis-derived compounds continues to grow, researchers are exploring whether cannabidiol (CBD) could offer a new option for patients struggling with difficult-to-treat pain. Unlike THC, CBD does not produce intoxicating effects, making it an appealing candidate for medical research.

A 2026 published clinical trial¹ in eClinicalMedicine examined whether high doses of CBD could help reduce neuropathic pain associated with spinal cord injury. The findings add to a growing body of evidence suggesting that cannabinoids may have a role in pain management, while also highlighting the challenges patients face when trying to access therapeutic doses. Let’s dive into the study and what it could mean for the future of pain management.

Understanding Neuropathic Pain

Neuropathic pain occurs when nerves themselves are damaged or disrupted. In people with spinal cord injuries, altered communication between the spinal cord and brain can create persistent pain signals even when no new injury is occurring. This type of pain can be particularly difficult to manage. Conventional treatments often include antidepressants, anticonvulsants, and opioid medications, but many patients continue to experience significant discomfort despite treatment. Side effects such as drowsiness, dizziness, and cognitive impairment can further complicate long-term management.

As a result, researchers have increasingly looked toward alternative approaches, including cannabinoids, for potential relief.

Why Researchers Studied CBD

CBD has attracted scientific interest because of its interactions with multiple biological systems involved in pain regulation. Preclinical studies have suggested that CBD may influence inflammation, nerve signaling, and other pathways linked to chronic pain. While animal studies have produced encouraging results, clinical evidence in humans has remained limited, particularly among people with spinal cord injuries. Researchers designed the recent trial to determine whether a high-dose CBD regimen could produce meaningful improvements in neuropathic pain under rigorous clinical conditions.

How the Clinical Trial Worked

The study was conducted at Neuroscience Research Australia and used a randomized, double-blind, placebo-controlled crossover design, which is considered one of the strongest methods for evaluating treatment effectiveness.

Forty adults with spinal cord injuries and neuropathic pain lasting at least three months were enrolled between August 2022 and December 2024. Participants received both CBD and placebo during separate treatment periods, allowing each person to serve as their own comparison.

Each treatment period lasted six weeks and was separated by a four-week washout period. CBD doses were gradually increased over two weeks until participants reached as much as 800 milligrams per day. Neither participants nor most members of the research team knew which treatment was being administered at any given time, helping reduce bias in the results. Researchers then measured changes in self-reported pain intensity using a standard visual analogue scale ranging from zero to ten.

CBD Reduced Pain Intensity

When researchers analyzed the data, they found a significant reduction in pain intensity during the active CBD treatment phase compared with placebo. Participants reported an average pain score of 3.82 during active CBD treatment. Researchers found pain scores were approximately 0.54 points lower compared with placebo treatment, a difference that reached statistical significance. While that reduction may appear modest on a ten-point pain scale, neuropathic pain associated with spinal cord injury is often difficult to treat, and even small improvements can be meaningful when experienced consistently over time.

Importantly, researchers did not observe meaningful differences between CBD and placebo during inactive treatment periods. This strengthens confidence that the reduction in pain was related to the CBD treatment rather than unrelated changes over time.

Another strength of the study is its crossover design. Because participants received both CBD and placebo at different points in the trial, researchers could directly compare each person’s response to treatment. This approach helps reduce variability between participants and provides a clearer picture of treatment effects. The findings suggest that high-dose CBD may provide measurable benefits for some patients with spinal cord injury-related nerve pain, particularly when existing therapies have not provided sufficient relief.

Safety and Tolerability Findings

Safety was another important focus of the trial. Researchers reported adverse events in approximately 68% of participants during CBD treatment and 53% during placebo treatment. However, nearly all reported side effects were classified as minor.

The study concluded that high-dose CBD was generally well tolerated, an important consideration given the substantial doses used. While side effects were somewhat more common during CBD treatment, the overall safety profile was favorable enough to support additional investigation.

As with any therapy, individual responses can vary, and larger studies will be needed to better understand long-term safety and effectiveness.

Why This Study Matters

Research on cannabinoids for pain has often produced mixed results, partly because many studies have been observational, involved small participant groups, or lacked rigorous placebo controls. This study stands out because it used a randomized, double-blind, placebo-controlled design, often considered the gold standard for evaluating medical treatments.

The findings do not prove that CBD should replace existing pain therapies, nor do they establish CBD as a cure for neuropathic pain. However, they provide evidence that CBD may have genuine therapeutic effects beyond placebo in people living with chronic spinal cord injury-related nerve pain.

The study also helps address an important gap in cannabinoid research. While many patients report using CBD products to manage chronic pain, relatively few controlled clinical trials have focused specifically on neuropathic pain following spinal cord injury.

Another noteworthy aspect of the research is the dose itself. Participants received up to 800 milligrams of CBD per day, substantially higher than the amounts commonly found in many wellness-focused CBD products. This suggests that therapeutic effects observed in clinical settings may require doses that differ significantly from those typically used by consumers, underscoring the need for further research into optimal dosing strategies.

What These Results Really Mean

The results should be viewed as encouraging but preliminary. The reduction in pain intensity was statistically significant, but the overall effect size was modest. Additional studies involving larger populations and longer follow-up periods will be needed to determine which patients are most likely to benefit, whether improvements can be sustained over time, and how CBD compares with existing treatment options.

Still, the findings add valuable clinical evidence to a field that has often relied on anecdotal reports and patient surveys. As researchers continue to investigate cannabinoid-based therapies, studies like this help build a stronger scientific foundation for future treatment decisions.

The Access and Affordability Challenge

Studies like this also highlight an issue that extends beyond the science itself: patient access. The therapeutic effects observed in this trial were achieved using doses of CBD that are substantially higher than what many commercially available products provide. Reaching hundreds of milligrams per day can become extremely expensive, particularly when patients must maintain treatment over months or years.

For many individuals living with chronic conditions, the cost of obtaining consistent, quality-controlled CBD products may place potentially beneficial therapies out of reach. This creates a disconnect between what researchers are studying in clinical settings and what patients can realistically afford in the real world.

The findings underscore the importance of thoughtful regulation, product quality standards, and medical access programs. As cannabinoid research advances, policymakers and healthcare systems need to consider how patients can access standardized products at clinically relevant doses without facing overwhelming financial barriers.

For medical cannabis patients, this challenge extends beyond CBD alone. Research increasingly examines cannabinoids at doses that may be difficult or costly to obtain through retail markets. Developing regulatory frameworks that support product consistency, affordability, and appropriate medical access could help ensure that patients are not excluded from potentially beneficial therapies simply because of cost.

Final Thoughts

Chronic neuropathic pain following spinal cord injury remains a major unmet medical challenge, and many patients continue to search for effective treatment options. This clinical trial suggests that high-dose CBD may offer modest but meaningful reductions in nerve pain while maintaining a generally favorable safety profile. Although further studies are needed to confirm the findings and explore long-term outcomes, the research adds valuable evidence to the growing conversation surrounding cannabinoids and pain management.

As scientists continue to investigate CBD’s therapeutic potential, studies like this help move the field beyond anecdotal reports and toward evidence-based understanding. Just as importantly, they raise important questions about ensuring that patients can access safe, regulated, and affordable cannabinoid therapies if future research continues to support their use.

References:

^{1. Robertson R, Suraev A, McCartney D et al., High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial, eClinicalMedicine, 2026; 96}